CLSD
Clearside Biomedical Inc.
Company Overview
| Mkt Cap | $18.74M | Price | $2.72 |
| Volume | 26.44K | Change | +4.21% |
| P/E Ratio | -0.5 | Open | $2.69 |
| Revenue | $1.7M | Prev Close | $2.61 |
| Net Income | $-34.4M | 52W Range | $0.29 - $17.10 |
| Div Yield | N/A | Target | $59.97 |
| Overall | 29 | Value | 40 |
| Quality | -- | Technical | 18 |
No chart data available
About Clearside Biomedical Inc.
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Latest News
Clearside Biomedical Inc. Explores Strategic Alternatives
VTI ETF Daily Report: 11/10/2025
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CLSD | $2.72 | +4.2% | 26.44K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Clearside Biomedical Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW